ClinicalTrials.gg
RecruitingNCT07013331DRAPETONINEUpdated May 8, 2026

A PET-MRI Study of Serotoninergic Brainstem Pathway in Patients With Dravet Syndrome

An interventional study of [18F]MPPF PET-MRI in Epilepsy, Dravet Syndrome and Drug Resistant Epilepsy, sponsored by Hospices Civils de Lyon. Recruiting at 1 site in France. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-08.

Sponsored by Hospices Civils de Lyon · Not applicable, Interventional, and Screening

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Epilepsy by Hospices Civils de Lyon — 12 open to participants now, 13 under way, none of them phase 3. Epilepsy · Hospices Civils de Lyon.

Planned enrollment
18th of 20
30 · median 70
Started
2026
with 5 others
No phase
16 of 27
7 open now
Primary completion
2028-01
later than 5 of 12 live
Registered
21st of 27
by date

Among the 27 studies in Epilepsy by Hospices Civils de Lyon, this one is the 18th largest by planned enrollment of the 20 interventional ones that give a count, is one of 6 that started in 2026, is one of 16 with no phase, reaches primary completion later than 5 of the 12 other live ones, and was the 21st registered.

Epilepsy

1,850 studies on the registry are indexed under Epilepsy; 418 are open to participants now.

Browse Epilepsy studies →

Open to participants now

12 of the 27 studies in Epilepsy by Hospices Civils de Lyon are open now, in 2 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Where they have run

Who these studies take

Of the 284 Epilepsy studies recruiting now, 113 (40%) set no upper age limit and 148 (52%) stop at 75 or younger; 138 take children under 18; 54 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Epilepsy by Hospices Civils de Lyon, or all of them as a file.
02

Study summary

Dravet Syndrome (DS) is a severe neurodevelopmental disease, which is predominantly caused by mutations of SCN1A, the gene coding for Nav1.1 voltage-gated sodium channels. DS is characterized by infancy onset, severe cognitive deficit and drug-resistant seizures, including several generalized convulsive seizures per day and frequent status epilepticus, often triggered by fever or hyperthermia. Among the causes of premature deaths in patients with epilepsy, sudden and unexpected death in epilepsy (SUDEP) represents a major cause. SUDEP is a non-traumatic and non-drowning death in patients with epilepsy, unrelated to a documented status epilepticus. The risk of SUDEP is particularly high in patients suffering from DS, reaching about 9/1000-person-year, as compared to about 1/1000-person-year in people with epilepsy including all disease types. The main clinical risk factor of SUDEP is the frequency of convulsive seizures. Beyond improving seizure control, which we showed to mitigate the SUDEP risk, more specific preventive treatment strategies are still lacking.

Experimental and clinical data suggest that most SUDEP cases result from postictal brainstem dysfunction, including central respiratory arrest There is a body of evidence suggesting involvement of serotonin (5HT) dysfunction both in the pathogenesis of epilepsy in DS and in seizure-related respiratory dysfunction. Serotonin indeed plays a key role in the regulation of respiration. Population firing of serotoninergic neurons in the medullary raphe is significantly decreased during the ictal and post-ictal periods, in association with decreased breathing and heart rate during and after seizures. Most importantly, post-mortem data in patients, including DS, showed alteration of neuronal populations in the medulla in SUDEP cases with evidence for greater reduction in neuromodulatory neuropeptidergic and monoaminergic, including serotoninergic, systems.

SUDEP in DS might therefore be the result of a seizure-induced fatal apnea in a patient who has developed epilepsy-related vulnerability to central respiratory dysfunction favored by 5HT dysfunction. However, several issues remain to be addressed to identify detailed mechanisms and effective therapies. Among them, a key issue is the exact relation between the alterations of the 5HT pathway observed in DS and epilepsy-related respiratory dysfunction

In the present study, the hypothesis is that adult patients with DS might demonstrate specific alterations of the 5HT pathway within the brainstem as assessed by PET imaging. The DRAPETOTINE study will thus focus on imaging 5HT brainstem pathway with PET and MRI in patients with DS to assess if abnormalities can be observed and through comparison with data collected in patients drug-resistant focal epilepsy whether these abnormalities are DS specficic or reflect the consequence on brainstem 5HT pathway of refractory seizures.

This study will involve 20 adult patients, including 10 adults with established diagnosis of Dravet Syndrome and 10 patients with drug-resistant focal epilepsy. Ten healthy adults will also be included. Participants will be recruited over a period of 18 months and the duration of participation for each participant will be 2 weeks to 8 weeks

03

Conditions studied

  • Epilepsy
  • Dravet Syndrome
  • Drug Resistant Epilepsy
  • Healthy Controls

Keywords

  • epilepsy
  • Dravet syndrome
  • drug-resistant focal epilepsy
  • serotonin
  • PET-MRI
  • MPPF
  • SUDEP
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Patients with DS

  • Inclusion criteria

    1. Adult patients (≥ 18 but \< 60 years)
    2. Diagnosis of Dravet syndrome will be confirmed based on medical history, type of seizures, EEG data and results of genetic testing
    3. No restriction related to the seizure frequency
    4. Patient assent and patient (or patient's legal representative guardianship) who gave its written to participate to the study
    5. For women of childbearing
  • Exclusion criteria

    1. Subject in exclusion period of another study
    2. MRI (presence of metallic elements, claustrophobia, Patients unable to maintain a minimul level of immobility during the imaging acquisition)
    3. Presence of Vagal Nerve Stimulation
    4. Patients unable to maintain a minimul level of immobility during the imaging acquisition
    5. Pregnant women, women in labor or breastfeeding women.
    6. Severe renal failure ( \< 30 ml/min)
    7. to [18F] MPPF
    8. Persons deprived of their liberty by a judicial or administrative decision
    9. Persons under psychiatric care
    10. Persons not affiliated to a social security scheme or beneficiaries of a similar scheme

Patients with drug-resistant focal epilepsy

  • Inclusion criteria

    1. Adult patient (≥ 18 years)
    2. Patient suffering from drug-resistant focal epilepsy according to ILAE classification
    3. Patient in whom presurgical evaluation is considered
    4. No restriction related to the seizure frequency
    5. Patient who gave her/his written informed consent to participate to the study
    6. For women of , use highly effective during study participation
  • Exclusion criteria

    1. Subject in exclusion period of another study
    2. MRI contra-indication (presence of metallic elements, claustrophobia)
    3. Presence of Vagal Nerve Stimulation
    4. Ongoing serotoninergic treatment, including selective serotonin reuptake inhibitor
    5. Pregnant women, women in labor or breastfeeding women.
    6. Severe renal failure (Glomerular filtration rate \< 30 ml/min)
    7. Hypersensitivity to [18F] MPPF
    8. Persons deprived of their liberty by a judicial or administrative decision
    9. Persons under psychiatric care
    10. Persons admitted to a health or social institution for purposes other than research
    11. Adults subject to a legal protection measure (guardianship, curatorship)
    12. Persons not affiliated to a social security scheme or beneficiaries of a similar scheme

Healthy controls

  • Inclusion criteria

    1. Presence of the symptoms of anxiety and/or depression as defined by a score ≥ 11 at the French version of the Hospital Anxiety and Depression Scale (HADS)
    2. Ongoing treatment with selective serotonin reuptake inhibitor
    3. MRI contra-indication (presence of metallic elements, claustrophobia)
    4. Pregnant women, women in labor or breastfeeding women.
    5. Severe renal failure (Glomerular filtration rate \< 30 ml/min)
    6. Hypersensitivity to [18F] MPPF
    7. Persons deprived of their liberty by a judicial or administrative decision
    8. Persons under psychiatric care
    9. Persons admitted to a health or social institution for purposes other than research
    10. Adults subject to a legal protection measure (guardianship, curatorship)
    11. Persons not affiliated to a social security scheme or beneficiaries of a similar scheme
  • Exclusion criteria

    1. Presence of the symptoms of anxiety and/or depression as defined by a score ≥ 11 at the French version of the Hospital Anxiety and Depression Scale (HADS)
    2. Ongoing treatment with selective serotonin reuptake inhibitor
    3. MRI contra-indication (presence of metallic elements, claustrophobia)
    4. Pregnant women, women in labor or breastfeeding women.
    5. Severe renal failure (Glomerular filtration rate \< 30 ml/min)
    6. Hypersensitivity to [18F] MPPF
    7. Persons deprived of their liberty by a judicial or administrative decision
    8. Persons under psychiatric care
    9. Persons admitted to a health or social institution for purposes other than research
    10. Adults subject to a legal protection measure (guardianship, curatorship)
    11. Persons not affiliated to a social security scheme or beneficiaries of a similar scheme
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Patients with Dravet syndrome

    Adult patients with Dravet syndrome (\> 18 and \< 60 years). Diagnosis of Dravet syndrome will be confirmed based on medical history, type of seizures, EEG data and results of genetic testing. Ten DS patients will be recruited and will be passed the PET-IRM with injection of the tracer \[18F\]MPPF.

    Other: [18F]MPPF PET-MRI

  • Experimental
    Patients with drug-resistant focal epilepsy

    Adult patients (\> 18 years) with drug-resistant focal epilepsy, as defined by the ILAE, and whom presurgical evaluation is considered. Ten patients will be recruited and will be passed the PET-IRM with injection of the tracer \[18F\]MPPF.

    Other: [18F]MPPF PET-MRI

  • Experimental
    Adult healthy controls (> 18 years)

    Ten healthy controls will be recruited and will be passed the PET-IRM with injection of the tracer \[18F\]MPPF. Participants must be of legal age.

    Other: [18F]MPPF PET-MRI

Interventions

  • Other[18F]MPPF PET-MRI

    Patients will be seen during an first inclusion visit during which a review of eligibility criteria, medical history and a clinical examination will be done. Participants will be scheduled for a PET-MRI scan within 2 to 8 weeks. For all women of childbearing age a urine pregnancy test will be performed before the PET-MRI. Anatomical MR imaging will be first acquired for anatomical co-registration and morphometry analyses (Neuromelanin sensitive images and 3D anatomical T1-weighted covering the whole brain volume with 1mm3 cubic voxels) After i.v. injection of a bolus of 180 MBq ± 10%, with a maximum of 198 MBq MBq, of \[18F\]-MPPF, a dynamic emission scan consisting of 35 frames of increasing duration (20s to 5min) will be acquired over 90-min post-injection

06

What researchers measure

Primary outcomes

  1. Comparison of the brainstem BPND of [18F]-MPPF across patients groups (DS and focal epilepsy)

    Dynamic PET images will be modelled using a simplified reference tissue model to estimate non-displaceable binding potential (BPND) values in each voxel with reference to the cerebellar white matter excluding the vermis.

    Time frame: Emission will be acquired over 90 minutes post-injection

Secondary outcomes

  1. Relation between the brainstem BPND of [18F]-MPPF and the total duration of central sleep apneas during total sleep time over a 24-hour period in patients with DS

    The total duration of central sleep apnea has been preferred to the total number of episodes of central sleep apnea as primary endpoint in order to take into account both the occurrence rate and the severity of episodes. To take into account the variability of the total sleep time across patients, the total duration of central sleep apneas will be expressed as the percentage of the total sleep time for each patient. Sleep apneas can classified as obstructive, central or both central sleep apnea, Apnea will be defined as a decrease in peak nasal pressure of \>90% of baseline, lasting at least 10 s. Hypopnea was defined as a decrease of \>30% of the baseline nasal pressure, lasting at least 10 s and associated with ≥4% drop in SpO2. Central apnea will be defined by cessation \> 10 seconds of airflow with simultaneous cessation of respiratory effort. The respiratory events are scored in clinical routine according to the 2007 American Academy of Sleep Medicine guidelines.

    Time frame: at Visit 2 (week 2)

  2. Comparing brainstem volume of patients with DS with the one of patients with drug-resistant focal epilepsy

    Comparing VBM on the brainstem parcels of patients with DS with the one of patients with drug-resistant focal epilepsy

    Time frame: at Visit 2 (week 2)

  3. Relation in DS between brainstem volumes and the total duration of central sleep apneas during total sleep time over a 24-hour period

    Time frame: at Visit 2 (week 2)

  4. Signal-noise radioactivity ratio of 5-HT1A receptors binding in healthy subjects

    Comparing the signal-noise radioactivity ratio of 5-HT1A receptors binding in healthy subjects with the one observed with the old PET camera used to develop the CERMEP normative database of 5-HT1A receptors binding in adults

    Time frame: at Visit 2 (week 2)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Jan 2028, 20 months after the start.

Of 339 non-industry interventional studies with no phase under Epilepsy, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 77. This study's planned 20 months is below that.

Counting every sponsor, half of 360 studies reached it within 42 months; a quarter within 19 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2025
First posted
Jun 10, 2025
StartActual
May 4, 2026
Primary completionEst.
Jan 4, 2028
CompletionEst.
Jan 4, 2028
Last update
May 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07013331
Responsible party
Sponsor
First posted
Jun 10, 2025
Start date
May 4, 2026
Primary completion
Jan 4, 2028 (estimated)
Completion
Jan 4, 2028 (estimated)
Last update
May 8, 2026

Study contacts

Sylvain Rheims, Pr
Contact
Sylvain.rheims@chu-lyon.fr
0472357106 ext. +33
Camille Giraudon, Dr
Contact
Camille.giraudon@chu-lyon.fr
04 26 73 94 38 ext. +33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion